Literature DB >> 3123253

Abnormal regulation of LDL receptor activity and abnormal cellular metabolism of hypertriglyceridaemic low density lipoprotein: normalization with bezafibrate therapy.

Y Kleinman1, Y Oschry, S Eisenberg.   

Abstract

The regulation of LDL (B,E) receptor activity and of cellular LDL protein metabolism by hypertriglyceridaemic (HTG) low density lipoprotein before and during hypolipidaemic therapy (with bezafibrate (BZ] were determined in cultured human skin fibroblasts. Defective binding and subnormal capacity to regulate LDL receptor activity was found for HTG-LDL. Binding affinity (Kd) of HTG-LDL to the receptor was 4.97 x 10(-8) M and of N-LDL, 1.74 x 10(-8) M. When assayed with normal 125I-LDL, the capacity of HTG-LDL to down-regulate receptor activity was 46-68% less than N-LDL. Both abnormalities reverted towards normal during treatment. The cellular metabolism of HTG-, BZ- and N-LDL in cells grown for 48 h with the respective lipoproteins was determined. In spite of their defective binding to the receptor, the metabolism of HTG-LDL in the regulated cells was accelerated in comparison to N-LDL, and equal to that of BZ-LDL. That observation is explained by the inefficient ability of HTG-LDL to depress LDL receptor activities in the cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3123253     DOI: 10.1111/j.1365-2362.1987.tb01154.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  5 in total

1.  Reduction of BM 15.766-induced 7-dehydrocholesterol accumulation by bezafibrate and mevinolin in rats. A non-isotopic in vivo test system for compounds reducing cholesterol synthesis.

Authors:  J Pill; E C Witte; F H Schmidt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-06       Impact factor: 3.000

2.  Acarbose is an effective adjunct to dietary therapy in the treatment of hypertriglyceridaemias.

Authors:  M Malaguarnera; I Giugno; P Ruello; M Rizzo; M Motta; G Mazzoleni
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

3.  Increased affinity of LDL for their receptors after acipimox treatment in hypertriglyceridemia.

Authors:  G Franceschini; F Bernini; S Michelagnoli; S Bellosta; V Vaccarino; C Torre; F Pazzucconi; R Fumagalli; C R Sirtori
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.

Authors:  K L Goa; L B Barradell; G L Plosker
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

Review 5.  Pharmacological control of hypertriglyceridemia.

Authors:  G Franceschini; R Paoletti
Journal:  Cardiovasc Drugs Ther       Date:  1993-06       Impact factor: 3.727

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.